Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Revenue of Verve Therapeutics, Inc. (VERV)
Revenue in 2023 (TTM): $11.76 M
According to Verve Therapeutics, Inc.'s latest financial reports the company's current revenue (TTM) is $11.76 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Verve Therapeutics, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $11.76 M | $6.3 M | $-217,669,000 | $-199,793,000 | $-200,068,000 |
| 2022 | $1.94 M | $-4,770,000 | $-162,883,000 | $-157,334,000 | $-157,387,000 |
| 2021 | $ | $-3,377,000 | $-85,532,000 | $-120,314,000 | $-118,637,000 |
| 2020 | $ | $-1,328,000 | $-39,299,000 | $-45,704,000 | $-45,542,000 |
| 2019 | $ | $-106,000 | $-13,536,000 | $-19,297,000 | $-19,019,000 |